Japan Tumor Profiling Market Size, Share, and COVID-19 Impact Analysis, By Technique (Genomics, Proteomics, Epigenetics, and Metabolomics), By Application (Personalized Cancer Medicine, Oncological Diagnostics, and Research), and Japan Tumor Profiling Market Insights, Industry Trend, Forecasts to 2035

Japan Tumor Profiling Market Insights Forecasts to 2035

• The Japan Tumor Profiling Market Size Was Estimated at USD 607.4 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 12.2% from 2025 to 2035
• The Japan Tumor Profiling Market Size is Expected to Reach USD 2154.8 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the Japan Tumor Profiling Market Size is Anticipated to Reach USD 2154.8 Million by 2035, Growing at a CAGR of 12.2% from 2025 to 2035. The Japan tumor profiling market is increasing owing to an increase in cancer cases, advances in personalized medicine, and robust government R&D initiatives. Early detection initiatives, sophisticated diagnostics, and high adoption of companion diagnostics for targeted therapies also fuel growth.

Market Overview

The Japan tumor profiling market refers to diagnostic methods, such as next generation sequencing, PCR, immunoassays, and liquid biopsies, used to interrogate genetic mutations in tumors for personalized treatment, prognostics, and research. Its strengths are Japan strong health infrastructure, regulatory support, and a set of established genomic medicine programs like SCRUM Japan and TOP GEAR.  Opportunities in Japan tumor profiling market stem from AI integration, broader use of liquid biopsies, growth in companion diagnostics, and strengthened academic–industry partnerships. Key market drivers include rising cancer cases, growing demand for precision medicine, technological advancements, and increased government investment in research and innovation. Government initiatives supporting this growth include national insurance coverage for cancer genomic profiling (since 2019), the development of clinical guidelines, the launch of the C-CAT clinical trial database, and the "Patient Requested Medical Care System" for divergent treatments.

Report Coverage

This research report categorizes the market for the Japan tumor profiling market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan tumor profiling market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan tumor profiling market.

Driving Factors

The Japan tumor profiling market is driven by a rising cancer incidence, growing demand for precision medicine, and advancements in genomic technologies like next-generation sequencing and liquid biopsies. Supportive government policies, including insurance coverage for cancer genomic profiling, have further accelerated adoption. Japan strong research infrastructure and active collaborations between academia and industry foster continuous innovation. Additionally, increasing awareness among clinicians and patients about the benefits of personalized treatment approaches is contributing to market growth, positioning tumor profiling as essential in modern oncology care.

Restraining Factors

The Japan tumor profiling market faces challenges such as high test costs, limited access in rural areas, and delays in clinical application. Regulatory hurdles and a shortage of skilled genomic professionals further hinder widespread adoption and effective implementation of profiling technologies.

Market Segmentation

The Japan tumor profiling market share is classified into technique and application.

• The genomics segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan tumor profiling market is segmented by technique into genomics, proteomics, epigenetics, and metabolomics. Among these, the genomics segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to its high precision in the identification of genetic mutations, the direction of targeted therapies, and the facilitation of personalized cancer therapy. Its owing to the impetus of high throughput sequencing technologies, well established research infrastructure, and extensive government funding of genomics-based medicine.

• The personalized cancer medicine segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan tumor profiling market is segmented by application into personalized cancer medicine, oncological diagnostics, and research. Among these, the personalized cancer medicine segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.  This is attributed to it improving the efficacy of treatment, reducing adverse effects, and concurs with government supported precision medicine initiatives, leading to widespread adoption in clinical oncology.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan tumor profiling market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Illumina, Inc.
• Fujirebio
• NeoGenomics Laboratories
• Thermo Fisher Scientific
• Otsuka Pharmaceutical Co., Ltd.
• Sysmex Corporation
• Shimadzu Corporation
• Daiichi Sankyo
• Taiho Pharmaceutical
• QIAGEN
• Agilent Technologies
• Shionogi & Co., Ltd.
• PerkinElmer
• Others

Recent Developments:

• In May 2025, Illumina, Inc., a worldwide leader in DNA sequencing, announced it had received approval from the Japan Ministry of Health, Labour and Welfare for its TruSight™ Oncology Comprehensive as a Class III/IV Specially Controlled Medical Device. This test aims to increase access to precision oncology in Japan, helping oncologists leverage genomic insights to improve cancer diagnosis and personalized treatment outcomes.
• In March 2025, Otsuka Pharmaceutical Co., Ltd. announced that HemeSite®, the Japan first comprehensive genomic profiling test for hematological malignancies, is now covered by the national health insurance system, increasing access to personalized diagnostics and supporting precision treatment for patients with blood-related cancers.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan tumor profiling market based on the below-mentioned segments:

Japan Tumor Profiling Market, By Technique

• Genomics
• Proteomics
• Epigenetics
• Metabolomics

Japan Tumor Profiling Market, By Application

• Personalized Cancer Medicine
• Oncological Diagnostics
• Research